Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Twist BioscienceTWST +4.43%69 EV-to-EBITDA is -62.80 as of Aug. 07, 2026. GuruFocus rates TWST with a GF Score™ of 69/100 and a GF Value™ of $52.17 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 119 Medical Diagnostics & Research companies, Twist Bioscience ranks worse than 840335.29% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Twist Bioscience's enterprise value is $7,069.8 Mil.
Twist Bioscience's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-112.6 Mil. Therefore, Twist Bioscience's EV-to-EBITDA for today is -62.80.
The historical rank and industry rank for Twist Bioscience's EV-to-EBITDA or its related term are showing as below:
TWST'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -75.47 Med: -12.43 Max: -2.01
Current: -62.8
During the past 10 years, the highest EV-to-EBITDA of Twist Bioscience was -2.01. The lowest was -75.47. And the median was -12.43.
TWST's EV-to-EBITDA is ranked worse than 100% of 119
companies
in the Medical Diagnostics & Research industry
Industry Median: 15.95
vs TWST: -62.80
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Twist Bioscience's PE Ratio (TTM) for today is calculated as:
Twist Bioscience's share price for today is $113.91.
Twist Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.220.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Twist Bioscience's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Twist Bioscience's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Twist Bioscience EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Twist Bioscience's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Twist Bioscience's EV-to-EBITDA falls into.
Twist Bioscience's current Enterprise Value is $7,069.8 Mil.
Twist Bioscience's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-112.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Twist Bioscience (TWST) has a EV-to-EBITDA of -62.80 as of Aug. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Twist Bioscience. According to the industry distribution chart, Twist Bioscience ranks #999999 out of 119 companies in the Medical Diagnostics & Research industry.
Is Twist Bioscience's EV-to-EBITDA too high?
Twist Bioscience's current EV-to-EBITDA is -62.80. Based on the distribution chart, Twist Bioscience ranks #999999 out of 119 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Twist Bioscience has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Twist Bioscience's EV-to-EBITDA compare to BLLN and SHC?
According to the Medical Diagnostics & Research industry distribution chart, Twist Bioscience ranks #999999 out of 119 companies for EV-to-EBITDA. This places Twist Bioscience in the lower half of its industry. The industry median EV-to-EBITDA is 15.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 15.95, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Twist Bioscience. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Twist Bioscience's current EV-to-EBITDA is -62.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Twist Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Twist Bioscience (TWST) is currently considered Significantly Overvalued. The stock's GF Value™ is $52.17, compared to a current price of $113.91 — trading 118.3% above its estimated fair value. The current EV-to-EBITDA is -62.80. Twist Bioscience's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Twist Bioscience (TWST), the current EV-to-EBITDA is -62.80 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Twist Bioscience (TWST) Overvalued in 2026?
Based on GuruFocus' analysis, Twist Bioscience stock appears to be overvalued.
The current stock price of $113.91 is trading 118.3% above its estimated GF Value™ of $52.17.
GuruFocus considers Twist Bioscience to be Significantly Overvalued.
Key valuation signals for TWST:
EV-to-EBITDA: -62.80
GF Value™: $52.17 vs. price of $113.91 (118.3% above fair value)
No single metric tells the full story. See the TWST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
69GF Score
Get the complete analysis for TWST
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TWST has been successfully added to your 
